A MediCom Oncology Site
This website uses cookies. By using our site you agree to our privacy policy
Username:
Password:
Lost username/password
Create an account
  • Home
  • About Us
    • Contact Us
    • Accreditation
    • MediCom Worldwide, Inc.
  • Reference
    • What is Multiple Myeloma?
    • FAQ Library
    • Clinical Pearls Podcasts
  • CE Education
    • Developments in NDMM
    • Examining the Evidence in Frontline Therapy
    • Annual Meeting Highlights
    • Accredited E-Newsletter Series
    • Practice Essentials
  • Resources
    • Web Links
    • Newsletters

Clinical Pearls Podcasts

MediCom Oncology Clinical Pearls Podcasts provide practical, evidence-based recommendations on real-world issues in the clinical setting. For more tips and advice on best practices in patients, subscribe to our channel on iTunes.


What is the significance of minimal residual disease (MRD) as a surrogate marker in myeloma?
Shaji K. Kumar, MD
Clinical Pearls Podcasts published on April 7, 2021
Read More
How does adding a fourth drug to a myeloma treatment regimen affect the side effect burden?
Shaji K. Kumar, MD
Clinical Pearls Podcasts published on April 2, 2021
Read More
What is the rationale for utilizing quadruplet therapy for frontline treatment of myeloma?
Shaji K. Kumar, MD
Clinical Pearls Podcasts published on March 25, 2021
Read More
Targeting BCMA in Multiple Myeloma and the Approval of Belantamab Mafodotin
Sagar Lonial, MD, FACP
Clinical Pearls Podcasts published on October 30, 2020
Read More

Results 1 - 4 of 4

MediCom Worldwide, Inc. Links

ManagingAML.com | ManagingMDS.com | ManagingMPN.com | ManagingLymphoma.com | PracticalOncologist.com | MediComWorldwide.com

©2023 MediCom Worldwide, Inc. All rights reserved
  • Privacy, Terms, and Conditions
  • Contact Us